Company intelligence / Profile preview

HEC Biopharmaceutical

Dongguan, Guangdong, China

Ownership: Private
Employees: ~20000
Development stage: Other

Overview

HEC Biopharmaceutical has commercialized oseltamivir (trade name Kewei) and multiple macrolide antibiotics. It is China's largest producer of oseltamivir, holds a leading position in macrolide APIs, and has a strong pipeline of biosimilar insulins (multiple in Phase III and NDA), oral hepatitis C therapies (yimitasvir phosphate is commercialized, others in late-stage development), and notable clinical results—e.g., SVR12 up to 100% for hepatitis C drugs[2][3].

Therapeutic areas: EndocrinologyInfectious DiseasesGastroenterologyPulmonologyNeurology
Modalities: Small moleculeBiologicRecombinant proteinBiosimilarPeptidesAntibody
Industry: Pharma

Partnerships

Roche (oseltamivir license)Pfizer (API partner)Abbott Laboratories (API partner)

Beyond the preview

Go deeper on HEC Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEC Biopharmaceutical.

Explore the full profile